CoRegen

CoRegen is a private, pre-clinical biotech leveraging a foundational discovery from the O'Malley Lab at Baylor College of Medicine. Its platform involves engineering regulatory T cells (Tregs) by knocking out a specific steroid receptor coactivator (SRC) gene, which reprograms these cells to trigger a potent and precise anti-cancer immune response, as demonstrated in extensive mouse studies. With a veteran leadership team, strong academic validation including the 2023 Cozzarelli Prize, and a partnership for manufacturing, the company is targeting an IND filing in 2025 to initiate human trials. The goal is to develop a scalable, single-infusion outpatient therapy for multiple solid tumors.

A cell therapy platform based on engineering regulatory T cells (Tregs) by knocking out a single steroid receptor coactivator (SRC) gene. This genetic disruption reprograms Tregs to trigger a potent, targeted, and permanent anti-cancer immune response, designed to be non-toxic and administered as a single outpatient infusion.

CoRegen competes in the crowded but high-potential field of solid tumor cell therapy, facing competition from other biotechs developing engineered T cell therapies (CAR-T, TCR-T, TILs) and from large pharma with extensive immuno-oncology portfolios. Its differentiation hinges on its unique single-gene Treg approach and promising non-toxicity profile.